Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary - About
Lipocine Inc (LPCN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/16/2025: LPCN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -2.72% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 18.08M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 31753 | Beta 1.23 | 52 Weeks Range 3.20 - 11.79 | Updated Date 02/21/2025 |
52 Weeks Range 3.20 - 11.79 | Updated Date 02/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.75 |
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -51.19% | Operating Margin (TTM) -66.82% |
Management Effectiveness
Return on Assets (TTM) -14.56% | Return on Equity (TTM) -19.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -624528 | Price to Sales(TTM) 2.28 |
Enterprise Value -624528 | Price to Sales(TTM) 2.28 | ||
Enterprise Value to Revenue 0.62 | Enterprise Value to EBITDA 0.65 | Shares Outstanding 5347940 | Shares Floating 5192529 |
Shares Outstanding 5347940 | Shares Floating 5192529 | ||
Percent Insiders 2.91 | Percent Institutions 9.16 |
AI Summary
Lipocine Inc. - A Comprehensive Overview
Company Profile:
Detailed history and background:
Lipocine Inc. (NASDAQ: LPCN) was founded in 2009 and is headquartered in Salt Lake City, Utah. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative metabolic and endocrine therapies.
Core business areas:
- Developing therapies for metabolic and endocrine disorders: Lipocine focuses on addressing unmet needs in conditions such as obesity, hypercholesterolemia, diabetes, and osteoporosis.
- Clinical development programs: The company has several drug candidates in its pipeline, including LPCN 1021 (Tlando), a testosterone replacement therapy, and LPCN 1144, a novel, oral, once-daily treatment for nonalcoholic steatohepatitis (NASH).
Leadership team and corporate structure:
- Dr. Mahesh Patel, Chairman and CEO: Dr. Patel has over 25 years of experience in the pharmaceutical industry and has led several companies through successful drug development and commercialization.
- Dr. John Tkacz, Executive Vice President and Chief Medical Officer: Dr. Tkacz has over 20 years of experience in clinical development and regulatory affairs.
- Mr. Bruce Roberts, Chief Financial Officer: Mr. Roberts has over 20 years of experience in finance and accounting.
Top Products and Market Share:
Top products and offerings:
- Tlando: Tlando is an FDA-approved testosterone replacement therapy indicated for men with hypogonadism. It is marketed and distributed in the US by TherapeuticsMD, Inc. under a commercialization agreement with Lipocine.
- LPCN 1144: LPCN 1144 is in Phase 2b clinical development for the treatment of NASH.
Market share:
- Tlando: Tlando has a market share of approximately 2% in the US testosterone replacement therapy market.
- LPCN 1144: LPCN 1144 is still in development, and its market share will depend on the results of ongoing clinical trials and its eventual commercialization.
Competitor comparison:
- Tlando: Tlando competes with other testosterone replacement therapies, such as AndroGel, Axiron, and Fortesta.
- LPCN 1144: LPCN 1144 competes with other NASH treatments in development, such as obeticholic acid and elafibranor.
Total Addressable Market:
The global market for metabolic and endocrine disorders is estimated to be worth over $500 billion. The US market for these disorders is estimated to be worth over $200 billion.
Financial Performance:
Recent financial results:
- Revenue: $1.1 million in 2022
- Net income: ($34.3 million) in 2022
- Profit margins: Gross profit margin of 95.4% in 2022
- Earnings per share (EPS): ($0.93) in 2022
Year-over-year performance:
- Revenue decreased by 26.2% in 2022 compared to 2021.
- Net loss increased in 2022 compared to 2021.
Cash flow and balance sheet health:
- Cash and cash equivalents of $28.3 million as of December 31, 2022.
- Total debt of $14.8 million as of December 31, 2022.
Dividends and Shareholder Returns:
Dividend history:
Lipocine does not currently pay dividends.
Shareholder returns:
- Total shareholder return of -34.5% in the past year.
- Total shareholder return of -55.6% in the past five years.
Growth Trajectory:
Historical growth:
- Revenue has grown at a compound annual growth rate (CAGR) of 26.5% over the past five years.
- Net income has declined over the past five years.
Future growth projections:
- Future growth will depend on the success of Tlando in the market and the development of LPCN 1144.
Recent product launches and strategic initiatives:
- Launched Tlando in the US market in 2021.
- Initiated a Phase 2b clinical trial for LPCN 1144 in 2022.
Market Dynamics:
Current trends:
- Increasing prevalence of metabolic and endocrine disorders.
- Growing demand for novel and effective treatments.
Demand-supply scenario:
- High demand for effective treatments for metabolic and endocrine disorders.
- Limited supply of new and innovative treatments.
Technological advancements:
- Development of new drug delivery technologies.
- Use of artificial intelligence in drug discovery and development.
Company positioning:
- Lipocine is well-positioned to capitalize on the growing demand for metabolic and endocrine therapies.
- The company has a strong pipeline of drug candidates.
- The company has a experienced management team.
Competitors:
Key competitors:
- TherapeuticsMD, Inc. (TXMD)
- Intercept Pharmaceuticals, Inc. (ICPT)
- Genfit S.A. (GNFT)
Market share comparison:
| Company | Market Share |
|---|---|
| TherapeuticsMD | 10% |
| Intercept Pharmaceuticals | 5% |
| Genfit S.A. | 3% |
| Lipocine | 2% |
Competitive advantages and disadvantages:
- Advantages: Innovative pipeline of drug candidates, experienced management team.
- Disadvantages: Limited market share, early-stage clinical development programs.
Potential Challenges and Opportunities:
Key Challenges:
- Regulatory approval of LPCN 1144.
- Commercial success of Tlando in the US market.
- Competition from other companies developing similar treatments.
About Lipocine Inc
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 2013-10-22 | Co-Founder, Interim Principal Financial Officer, Director, President & CEO Dr. Mahesh V. Patel Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://www.lipocine.com |
Full time employees 17 | Website https://www.lipocine.com | ||
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.